Vosoritide - BioMarin Pharmaceutical
Alternative Names: BMN-111; Modified C-natriuretic peptide - BioMarin Pharmaceutical; Modified recombinant human C-type natriuretic peptide - BioMarin Pharmaceutical; ProCNP38; VOXZOGOLatest Information Update: 19 Sep 2024
Price :
$50 *
At a glance
- Originator BioMarin Pharmaceutical
- Class Cyclic peptides; Natriuretic agents; Natriuretic peptides; Recombinant proteins
- Mechanism of Action Atrial natriuretic factor receptor B agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Achondroplasia
- Phase III Hypochondroplasia
- Phase II Short stature
- Phase I Noonan syndrome; Turner's syndrome
Most Recent Events
- 19 Sep 2024 Phase-I clinical trials in Turner's syndrome (unspecified route) (BioMarin Pharmaceutical pipeline; September 2024)
- 04 Sep 2024 Phase-I clinical trials in Noonan syndrome (unspecified route) (BioMarin Pharmaceutical pipeline; September 2024)
- 04 Sep 2024 BioMarin plans potential approval of Vosoritide for Hypochondroplasia in 2027 (SC)